In a breast cancer dataset of 2051 cases [24], 36% of total cases (n = 734) had TP53 alterations and 25% (n = 513) had Diexf amplification, but only 6% (n = 134) had both (Figure 1B). Here, UTP25 is linked to breast cancer.